Covance Increases Its Phase I Clinical Capacity With Acquisition of GFI Research Center
Covance Inc. (NYSE: CVD http://rd.bcentral.com/?ID=3182929&s=81101478) added to its Phase I capacity and further enhanced its reputation for clinical excellence with the purchase today of GFI Clinical Services from West Pharmaceutical Services, Inc. (NYSE: WST).
Princeton, New Jersey – (August 23, 2005) – Covance Inc. (NYSE: CVD http://rd.bcentral.com/?ID=3182929&s=81101478) added to its Phase I capacity and further enhanced its reputation for clinical excellence with the purchase today of GFI Clinical Services from West Pharmaceutical Services, Inc. (NYSE: WST).
Covance acquired the assets of the Evansville, Indiana-based clinical research unit for $5.7 million. The 80-bed facility will now be part of Covance Clinical Research Unit Inc., and will be known as Covance GFI Research.
Covance has been looking to expand its clinical pharmacology presence in North America and GFI helps fill that need with a high quality asset, says Covance CEO Joe Herring. With continued high demand in the clinical pharmacology market, were pleased to have found a CRU with similar expertise and reputation in handling high-end, complex studies.
The purchase is welcome news to GFI and its 100 employees, remarks Christi Bradley, MBA, RD, Vice President and General Manager of GFI Clinical Services. Were very excited about being a part of Covance, as well as the prospect of growing and enhancing our clinical capabilities.
About Covance
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1 billion, global operations in 17 countries, and approximately 7,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com http://rd.bcentral.com/?ID=3182930&s=81101478 .
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
